Related references
Note: Only part of the references are listed.Adiposity May Predict Survival in Patients With Advanced Stage Cancer Treated With Immunotherapy in Phase 1 Clinical Trials
Dylan J. Martini et al.
CANCER (2020)
Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials
D. E. Magee et al.
ANNALS OF ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Determinants of Resistance to Checkpoint Inhibitors
Linda Tran et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
Mehmet Asim Bilen et al.
ONCOLOGIST (2020)
Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Dylan J. Martini et al.
ONCOLOGIST (2020)
Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
Julie M. Shabto et al.
CANCER MEDICINE (2020)
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
Florian R. Greten et al.
IMMUNITY (2019)
Prognostic significance of inflammation-based prognostic scoring in patients with upper urinary tract urothelial carcinoma
Taisuke Suyama et al.
INTERNATIONAL BRAZ J UROL (2019)
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors
Giuseppe Schepisi et al.
JOURNAL OF ONCOLOGY (2019)
Modified Glasgow Prognostic Score Predict Survival Among Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
C. Freitas et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy
Mehmet A. Bilen et al.
CANCER (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer
Shoji Kimura et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
Mehmet Asim Bilen et al.
CLINICAL GENITOURINARY CANCER (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Jason Zhu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions
Abhishek Tripathi et al.
CURRENT UROLOGY REPORTS (2018)
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
Cristina Vajaitu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan
Ryuji Matsumoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Sebastien Antoni et al.
EUROPEAN UROLOGY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma
Yu-Li Su et al.
PLOS ONE (2017)
The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma
Teruo Inamoto et al.
ONCOTARGET (2017)
Biomarkers for immunotherapy in bladder cancer: a moving target
David H. Aggen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma
Rishi R. Sekar et al.
ASIAN JOURNAL OF UROLOGY (2017)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma
Guru Sonpavde et al.
JOURNAL OF UROLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy A Multicenter Experience
Matteo Ferro et al.
MEDICINE (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Cancer-related inflammation and treatment effectiveness
Connie I. Diakos et al.
LANCET ONCOLOGY (2014)
Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy
Matthew D. Galsky et al.
CANCER (2013)
Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials
Guru Sonpavde et al.
EUROPEAN UROLOGY (2013)
An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
M. J. Proctor et al.
BRITISH JOURNAL OF CANCER (2011)
C-reactive protein as a biomarker for urological cancers
Kazutaka Saito et al.
NATURE REVIEWS UROLOGY (2011)
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
Digant Gupta et al.
NUTRITION JOURNAL (2010)
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2009)
Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens
Chia-Chi Lin et al.
UROLOGY (2007)
A systematic review of the association between circulating concentrations of C reactive protein and cancer
Katriina Heikkila et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2007)
Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPβ to the promoter
A Agrawal et al.
MOLECULAR IMMUNOLOGY (2003)
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer
LM Forrest et al.
BRITISH JOURNAL OF CANCER (2003)
Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss
DC McMillan et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2001)
Share Paper
